Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
M1 Kliniken AGMKLNF 90 Debt-to-Equity is 0.06 as of Dec. 2025, which is 50% below its 10-year median of 0.12. GuruFocus rates MKLNF with a GF Score™ of 90/100 and a GF Value™ of $9.78. The stock has 3 warning signs investors should review. Among 100 Medical Distribution companies, M1 Kliniken AG ranks better than 87% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for M1 Kliniken AG's Debt-to-Equity or its related term are showing as below:
MKLNF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.12 Max: 0.17
Current: 0.06
During the past 12 years, the highest Debt-to-Equity Ratio of M1 Kliniken AG was 0.17. The lowest was 0.06. And the median was 0.12.
MKLNF's Debt-to-Equity is ranked better than 87% of 100
companies
in the Medical Distribution industry
Industry Median: 0.48
vs MKLNF: 0.06
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
M1 Kliniken AG Debt-to-Equity Related Terms
M1 Kliniken AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for M1 Kliniken AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, M1 Kliniken AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
M1 Kliniken AG Debt-to-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, M1 Kliniken AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where M1 Kliniken AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
M1 Kliniken AG (MKLNF) has a Debt-to-Equity of 0.06 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on M1 Kliniken AG and its competitors. This is 50% below median its historical median of 0.12. Over the past decade, M1 Kliniken AG's Debt-to-Equity has ranged from 0.06 to 0.17. According to the industry distribution chart, M1 Kliniken AG ranks #13 out of 100 companies in the Medical Distribution industry, placing it in the top 13%.
Is M1 Kliniken AG's Debt-to-Equity too high?
M1 Kliniken AG's current Debt-to-Equity of 0.06 is 50% below median its 10-year median of 0.12. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.17. The Medical Distribution industry median Debt-to-Equity is 0.48. M1 Kliniken AG's value of 0.06 is 87.5% below this industry median. Based on the distribution chart, M1 Kliniken AG ranks #13 out of 100 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, M1 Kliniken AG has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does M1 Kliniken AG's Debt-to-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, M1 Kliniken AG ranks #13 out of 100 companies for Debt-to-Equity. This places M1 Kliniken AG in the top 13% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.48. M1 Kliniken AG's value of 0.06 is 87.5% below this benchmark. Historically, M1 Kliniken AG's own Debt-to-Equity has ranged from 0.06 to 0.17 over the past decade. While the company's 10-year median is 0.12 vs. the industry median of 0.48, M1 Kliniken AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.48, based on 100 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. M1 Kliniken AG's current Debt-to-Equity of 0.06 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on M1 Kliniken AG and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. M1 Kliniken AG's current Debt-to-Equity is 0.06, which is 50% below median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is M1 Kliniken AG stock overvalued right now?
M1 Kliniken AG (MKLNF) has a current Debt-to-Equity of 0.06. The stock's GF Value™ is $9.78, compared to a current price of $11.73 — trading 19.9% above its estimated fair value. The current Debt-to-Equity is 0.06, which is 50% below median its 10-year median of 0.12 and 87.5% below the Medical Distribution industry median of 0.48. M1 Kliniken AG's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For M1 Kliniken AG (MKLNF), the current Debt-to-Equity is 0.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is M1 Kliniken AG (MKLNF) Overvalued in 2026?
Based on GuruFocus' analysis, M1 Kliniken AG stock appears to be overvalued.
The current stock price of $11.73 is trading 19.9% above its estimated GF Value™ of $9.78.
Key valuation signals for MKLNF:
Debt-to-Equity: 0.06 (50% below median its 10-year median of 0.12)
GF Value™: $9.78 vs. price of $11.73 (19.9% above fair value)
Industry Position: 87.5% below the Medical Distribution median (#13 of 100)
No single metric tells the full story. See the MKLNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
M1 Kliniken AG operates in the growing market of aesthetic medicine and plastic surgery and provides aesthetic medical treatments in the self-pay segment. It operates through Beauty and Trade segments. Its activities are focused on providing aesthetic medical treatment. In addition to medical aesthetic treatments, the company also develops and markets pharmaceutical, medical, and medical technology products for aesthetic surgery and cosmetic dermatology. Some of the treatments offered by the group are lip under injection, eyebrow lift, tummy tuck, breast reduction, sweat treatment, liposuction, and others. The organization conducts its business operations in Germany. The majority of its revenue is derived from the Trade segment.
90GF Score
Get the complete analysis for MKLNF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MKLNF has been successfully added to your 
